Nuvalent
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 92
- Market Cap
- $5.4B
- Website
- http://www.nuvalent.com
- Introduction
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.
SEC Form 424B5 filed by Nuvalent Inc.
Lock-up agreements restrict parties from selling, transferring, or hedging lock-up securities, except for specified transactions like gifts, estate planning, transfers to family trusts, or upon death, disability, or termination of employment. Certain underwritten sales or early release from restrictions are also permitted under specific conditions.
© Copyright 2025. All Rights Reserved by MedPath